目的回顾性分析病毒性肝硬化患者血浆输注前后凝血功能指标的变化情况。方法以2014年6月～2016年6月延安大学附属医院所有诊断为病毒性肝硬化且首次输注血浆的86例住院患者病例资料为研究对象,采用凝固法检测凝血酶原时间(PT)、活化部...目的回顾性分析病毒性肝硬化患者血浆输注前后凝血功能指标的变化情况。方法以2014年6月～2016年6月延安大学附属医院所有诊断为病毒性肝硬化且首次输注血浆的86例住院患者病例资料为研究对象,采用凝固法检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)和纤维蛋白原(FIB)四项,胶乳免疫比浊法检测D-二聚体(D-Dimer,D-D)和纤维蛋白降解产物(fiber protein degradation product,FDP)。结果病毒性肝硬化患者输注血浆后PT值显著降低,APTT延长,D-D和FDP显著增高,差异均有统计学意义(t=8.00,4.46,7.07,8.27,均P<0.05),以年龄段、性别分组均有显著性变化,差异有统计学意义(P<0.05);病毒性肝硬化患者输注血浆前TT﹑FIB和输注血浆后相比无显著性变化(t=0.78,1.16,均P>0.05),以年龄段、性别分组均无显著性变化,差异无统计学意义(P>0.05)。结论病毒性肝硬化患者输注血浆后凝血功能得到改善。展开更多
Context: Previous findings indicate that vitamin K2 (menaquinone)may play a role in controlling cell growth.Objective: To determine whether vitamin K2 has preventive effects on the development of hepatocellular carcin...Context: Previous findings indicate that vitamin K2 (menaquinone)may play a role in controlling cell growth.Objective: To determine whether vitamin K2 has preventive effects on the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. Design, Setting, and Participants: Forty women diagnosed as having viral liver cirrhosis were admitted to a university hospital between 1996 and 1998 and were randomly assigned to the treatment or control group. The original goal of the trial was to assess the long-term effects of vitamin K2 on bone loss in women with viral liver cirrhosis. However, study participants also satisfied criteria required for examination of the effects of such treatment on the development of hepatocellular carcinoma.Interventions: The treatment control groups received symptomatic therapy to treat ascites, if necessary, and dietary advice. Main Outcome Measure: Cumulative proportion of patients with hepatocellular carcinoma. Results: Hepatocellular carcinomawas detected in 2 of the 21 women given vitamin K2 and 9 of the 19 women in the control group. The cumulative proportion of patients with hepatocellular carcinoma was smaller in the treatment group (log-rank test, P=.02).On univariate analysis, the risk ratio for the development of hepatocellular carcinoma in the treatment group compared with the control group was 0.20 (95% confidence interval CI, 0.04-0.91; P=.04). On multivariate analysis with adjustment for age, alanine aminotransferase activity,serum albumin, total bilirubin, platelet count, α-fetoprotein,and history of treatment with interferon alfa, the risk ratio for the development of hepatocellular carcinoma in patients given vitamin K2 was 0.13 (95% CI, 0.02-0.99;P=.05). Conclusion: There is a possible role for vitamin K2 in the prevention of hepatocellular carcinoma in women with viral cirrhosis.展开更多
文摘目的回顾性分析病毒性肝硬化患者血浆输注前后凝血功能指标的变化情况。方法以2014年6月～2016年6月延安大学附属医院所有诊断为病毒性肝硬化且首次输注血浆的86例住院患者病例资料为研究对象,采用凝固法检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)和纤维蛋白原(FIB)四项,胶乳免疫比浊法检测D-二聚体(D-Dimer,D-D)和纤维蛋白降解产物(fiber protein degradation product,FDP)。结果病毒性肝硬化患者输注血浆后PT值显著降低,APTT延长,D-D和FDP显著增高,差异均有统计学意义(t=8.00,4.46,7.07,8.27,均P<0.05),以年龄段、性别分组均有显著性变化,差异有统计学意义(P<0.05);病毒性肝硬化患者输注血浆前TT﹑FIB和输注血浆后相比无显著性变化(t=0.78,1.16,均P>0.05),以年龄段、性别分组均无显著性变化,差异无统计学意义(P>0.05)。结论病毒性肝硬化患者输注血浆后凝血功能得到改善。
文摘Context: Previous findings indicate that vitamin K2 (menaquinone)may play a role in controlling cell growth.Objective: To determine whether vitamin K2 has preventive effects on the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. Design, Setting, and Participants: Forty women diagnosed as having viral liver cirrhosis were admitted to a university hospital between 1996 and 1998 and were randomly assigned to the treatment or control group. The original goal of the trial was to assess the long-term effects of vitamin K2 on bone loss in women with viral liver cirrhosis. However, study participants also satisfied criteria required for examination of the effects of such treatment on the development of hepatocellular carcinoma.Interventions: The treatment control groups received symptomatic therapy to treat ascites, if necessary, and dietary advice. Main Outcome Measure: Cumulative proportion of patients with hepatocellular carcinoma. Results: Hepatocellular carcinomawas detected in 2 of the 21 women given vitamin K2 and 9 of the 19 women in the control group. The cumulative proportion of patients with hepatocellular carcinoma was smaller in the treatment group (log-rank test, P=.02).On univariate analysis, the risk ratio for the development of hepatocellular carcinoma in the treatment group compared with the control group was 0.20 (95% confidence interval CI, 0.04-0.91; P=.04). On multivariate analysis with adjustment for age, alanine aminotransferase activity,serum albumin, total bilirubin, platelet count, α-fetoprotein,and history of treatment with interferon alfa, the risk ratio for the development of hepatocellular carcinoma in patients given vitamin K2 was 0.13 (95% CI, 0.02-0.99;P=.05). Conclusion: There is a possible role for vitamin K2 in the prevention of hepatocellular carcinoma in women with viral cirrhosis.
